Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity
US10287299B2 · kind B2 · utility
1Cited by
2References
6Claims
0Family size
Assignee
Inventors
- Gareth Neil Brace
- Prafulkumar Tulshibhai Chovatia
- Gregory Foulkes
- James A. Johnson
- Severine Danielle Jones
- Boris Kroeplien
- Fabien Claude Lecomte
- Pui Leng Loke
- Martin Alexander Lowe
- Ajay Mandal
- Timothy John Norman
- Christopher Francis Palmer
- Yolanda Pérez-Fuertes
- John Robert Porter
- Donald Smyth
- Giancarlo Trani
- Muhammed Uddin
- Zhaoning Zhu
Key dates
| Filing date | Jun 7, 2016 |
| Grant date | May 14, 2019 |
| Priority date | — |
| Expiry date | Jun 7, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.